---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-025200"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:40:22.071574+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# DiaMedica updates on ReMEDy2 trial, starts preeclampsia study, extends cash to Q3 2026

## Summary
- ReMEDy2 AIS interim analysis enrollment (n=144) targeted for Q1 2025; 15 top U.S. centers prioritized.
- Phase 2 preeclampsia trial begins Q4 2024; proof-of-concept results expected H1 2025.
- Completed $11.8M private placement ($2.50/share, ~10% premium) in June 2024; net proceeds $11.7M.
- Cash, cash equivalents and investments $54.1M as of June 30, 2024; working capital $51.9M.
- R&D expenses $3.9M for Q2 2024 (up from $2.5M Q2 2023); net cash used in operations $11.2M H1 2024.

## SEC filing metadata
- accession: 0001437749-24-025200
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774924025200/0001437749-24-025200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774924025200/dmtp20240807_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-025200
- JSON: https://secwatch.observer/filing/0001437749-24-025200.json
- Plain text: https://secwatch.observer/filing/0001437749-24-025200.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.